{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T14:15:35Z","timestamp":1777731335224,"version":"3.51.4"},"reference-count":38,"publisher":"Association for Research in Vision and Ophthalmology (ARVO)","issue":"9","license":[{"start":{"date-parts":[[2021,8,18]],"date-time":"2021-08-18T00:00:00Z","timestamp":1629244800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Trans. Vis. Sci. Tech."],"published-print":{"date-parts":[[2021,8,18]]},"DOI":"10.1167\/tvst.10.9.21","type":"journal-article","created":{"date-parts":[[2021,8,18]],"date-time":"2021-08-18T15:45:12Z","timestamp":1629301512000},"page":"21","source":"Crossref","is-referenced-by-count":7,"title":["Comparison of Syringes With Intravitreal Anti-VEGF Drugs: Particle Burden and Protein Aggregates in Brolucizumab, Aflibercept and Bevacizumab"],"prefix":"10.1167","volume":"10","author":[{"given":"Marc","family":"Schargus","sequence":"first","affiliation":[{"name":"Department of Ophthalmology, Heinrich Heine University D\u00fcsseldorf, D\u00fcsseldorf, Germany"},{"name":"Department of Ophthalmology, Asklepios Hospital Nord-Heidberg, Hamburg, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katharina Tatjana","family":"Kopp","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Pharmaceutical Technology and Biopharmaceutics, Ludwig-Maximilians-University Munich, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Constanze","family":"Helbig","sequence":"additional","affiliation":[{"name":"Coriolis Pharma Research GmbH, Martinsried, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andreas","family":"Frings","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Heinrich Heine University D\u00fcsseldorf, D\u00fcsseldorf, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gerhard","family":"Winter","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Pharmaceutical Technology and Biopharmaceutics, Ludwig-Maximilians-University Munich, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"27","reference":[{"issue":"2","key":"bib1","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1016\/j.ajpath.2012.06.006","article-title":"A brief history of anti-VEGF for the treatment of ocular angiogenesis","volume":"181","author":"Kim","year":"2012","journal-title":"Am J Pathol"},{"issue":"6","key":"bib3","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1097\/IAE.0b013e3181d50cea","article-title":"High-molecular-weight aggregates in repackaged bevacizumab","volume":"30","author":"Kahook","year":"2010","journal-title":"Retina"},{"issue":"10","key":"bib4","doi-asserted-by":"publisher","first-page":"2088","DOI":"10.1097\/IAE.0000000000001809","article-title":"Contamination of anti-VEGF drugs for intravitreal injection: how do repackaging and newly developed syringes affect the amount of silicone oil droplets and protein aggregates?","volume":"38","author":"Schargus","year":"2018","journal-title":"Retina"},{"issue":"1","key":"bib5","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1001\/jamaophthalmol.2014.3591","article-title":"Evaluation of compounded bevacizumab prepared for intravitreal injection","volume":"133","author":"Yannuzzi","year":"2015","journal-title":"JAMA Ophthalmol"},{"issue":"9","key":"bib6","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1136\/bjophthalmol-2011-300654","article-title":"Aflibercept (VEGF Trap-eye): the newest anti-VEGF drug","volume":"96","author":"Stewart","year":"2012","journal-title":"Br J Ophthalmol"},{"issue":"17","key":"bib7","doi-asserted-by":"publisher","first-page":"11393","DOI":"10.1073\/pnas.172398299","article-title":"VEGF-Trap: a VEGF blocker with potent antitumor effects","volume":"99","author":"Holash","year":"2002","journal-title":"Proc Natl Acad Sci USA"},{"issue":"1","key":"bib8","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.mayocp.2011.10.001","article-title":"The expanding role of vascular endothelial growth factor inhibitors in ophthalmology","volume":"87","author":"Stewart","year":"2012","journal-title":"Mayo Clin Proc"},{"key":"bib11","doi-asserted-by":"publisher","first-page":"897","DOI":"10.2147\/OPTH.S207978","article-title":"Issues with intravitreal administration of anti-VEGF drugs","volume":"14","author":"Schargus","year":"2020","journal-title":"Clin Ophthalmol"},{"issue":"9","key":"bib12","doi-asserted-by":"publisher","first-page":"1802","DOI":"10.1016\/j.ophtha.2015.04.018","article-title":"Intraocular pressure in patients with neovascular age-related macular degeneration receiving intravitreal aflibercept or ranibizumab","volume":"122","author":"Freund","year":"2015","journal-title":"Ophthalmology"},{"issue":"5","key":"bib13","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.1016\/j.ophtha.2013.11.029","article-title":"Intraocular pressure in eyes receiving monthly ranibizumab in 2 pivotal age-related macular degeneration clinical trials","volume":"121","author":"Bakri","year":"2014","journal-title":"Ophthalmology"},{"issue":"7","key":"bib14","doi-asserted-by":"publisher","first-page":"996","DOI":"10.1097\/IAE.0b013e31816c6868","article-title":"Intravitreal silicone oil droplets after intravitreal drug injections","volume":"28","author":"Bakri","year":"2008","journal-title":"Retina"},{"key":"bib16","doi-asserted-by":"publisher","first-page":"100687","DOI":"10.1016\/j.ajoc.2020.100687","article-title":"Severe vision loss secondary to retinal arteriolar occlusions after multiple intravitreal brolucizumab administrations","volume":"18","author":"Jain","year":"2020","journal-title":"Am J Ophthalmol Case Rep"},{"key":"bib17","doi-asserted-by":"publisher","first-page":"100989","DOI":"10.1016\/j.ajoc.2020.100989","article-title":"Brolucizumab-related retinal vasculitis with exacerbation following ranibizumab retreatment: a clinicopathologic case study","volume":"20","author":"Iyer","year":"2020","journal-title":"Am J Ophthalmol Case Rep"},{"key":"bib18","article-title":"Risk of inflammation, retinal vasculitis, and retinal occlusion-related events with brolucizumab: post hoc review of HAWK and HARRIER","author":"Mon\u00e9s","year":"2020","journal-title":"Ophthalmology"},{"key":"bib19","doi-asserted-by":"crossref","DOI":"10.1016\/j.ophtha.2020.04.017","article-title":"Expert opinion on management of intraocular inflammation, retinal vasculitis, and vascular occlusion after brolucizumab treatment","author":"Baumal","year":"2020","journal-title":"Ophthalmol Retina"},{"issue":"4","key":"bib20","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1177\/2474126420930863","article-title":"Occlusive retinal vasculitis following intravitreal brolucizumab","volume":"4","author":"Witkin","year":"2020","journal-title":"J Vitreoretin Dis"},{"issue":"10","key":"bib21","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1016\/j.ophtha.2020.04.017","article-title":"Retinal vasculitis and intraocular inflammation after intravitreal injection of brolucizumab","volume":"127","author":"Baumal","year":"2020","journal-title":"Ophthalmology"},{"key":"bib22","doi-asserted-by":"publisher","first-page":"100680","DOI":"10.1016\/j.ajoc.2020.100680","article-title":"Retinal arterial occlusive vasculitis following intravitreal brolucizumab administration","volume":"18","author":"Haug","year":"2020","journal-title":"Am J Ophthalmol Case Rep"},{"issue":"5","key":"bib23","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1097\/IAE.0000000000000801","article-title":"Noninfectious vitritis after intravitreal injection of anti-VEGF agents: variations in rates and presentation by medication","volume":"36","author":"Williams","year":"2016","journal-title":"Retina"},{"issue":"4","key":"bib24","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1001\/jamaophthalmol.2014.5650","article-title":"Postmarketing analysis of aflibercept-related sterile intraocular inflammation","volume":"133","author":"Hahn","year":"2015","journal-title":"JAMA Ophthalmol"},{"key":"bib25","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s40942-018-0153-8","article-title":"Release of silicone oil droplets from syringes","volume":"5","author":"Melo","year":"2019","journal-title":"Int J Retina Vitreous"},{"issue":"9","key":"bib26","doi-asserted-by":"publisher","first-page":"e0137833","DOI":"10.1371\/journal.pone.0137833","article-title":"Intraocular pressure changes in non-glaucomatous patients receiving intravitreal anti-vascular endothelial growth factor agents","volume":"10","author":"Kiddee","year":"2015","journal-title":"PLoS One"},{"issue":"3","key":"bib27","doi-asserted-by":"publisher","first-page":"126","DOI":"10.3109\/08820538.2013.771195","article-title":"Incidence and management of elevated intraocular pressure with antivascular endothelial growth factor agents","volume":"28","author":"Abedi","year":"2013","journal-title":"Semin Ophthalmol"},{"issue":"1","key":"bib28","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1089\/jop.2009.0076","article-title":"Persistent ocular hypertension following intravitreal bevacizumab and ranibizumab injections","volume":"26","author":"Adelman","year":"2010","journal-title":"J Ocul Pharmacol Ther"},{"issue":"8","key":"bib29","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1136\/bjo.2010.180729","article-title":"Sustained elevation of intraocular pressure after intravitreal injections of anti-VEGF agents","volume":"95","author":"Good","year":"2011","journal-title":"Br J Ophthalmol"},{"issue":"1","key":"bib30","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1097\/IAE.0b013e318261a6f7","article-title":"Clinical predictors of sustained intraocular pressure elevation due to intravitreal anti-vascular endothelial growth factor therapy","volume":"33","author":"Hoang","year":"2013","journal-title":"Retina"},{"issue":"11","key":"bib31","doi-asserted-by":"publisher","first-page":"2161","DOI":"10.1097\/IAE.0000000000000264","article-title":"Intraocular pressure in patients with neovascular age-related macular degeneration switched to aflibercept injection after previous anti-vascular endothelial growth factor treatments","volume":"34","author":"Rusu","year":"2014","journal-title":"Retina"},{"issue":"1","key":"bib32","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1089\/jop.2014.0062","article-title":"High intraocular pressure following anti-vascular endothelial growth factor therapy: proposed pathophysiology due to altered nitric oxide metabolism","volume":"31","author":"Ricca","year":"2015","journal-title":"J Ocul Pharmacol Ther"},{"issue":"2","key":"bib33","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1167\/iovs.10-6431","article-title":"Silicone oil microdroplets and protein aggregates in repackaged bevacizumab and ranibizumab: effects of long-term storage and product mishandling","volume":"52","author":"Liu","year":"2011","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"9","key":"bib34","doi-asserted-by":"publisher","first-page":"2909","DOI":"10.1002\/jps.21566","article-title":"Protein aggregation: pathways, induction factors and analysis","volume":"98","author":"Mahler","year":"2009","journal-title":"J Pharm Sci"},{"issue":"1","key":"bib35","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/S0165-0270(01)00443-5","article-title":"Experimental glaucoma in the primate induced by latex microspheres","volume":"111","author":"Weber","year":"2001","journal-title":"J Neurosci Methods"},{"issue":"5","key":"bib36","doi-asserted-by":"publisher","first-page":"1520","DOI":"10.1002\/jps.23945","article-title":"Functional evaluation and characterization of a newly developed silicone oil-free prefillable syringe system","volume":"103","author":"Yoshino","year":"2014","journal-title":"J Pharm Sci"},{"issue":"9","key":"bib37","doi-asserted-by":"publisher","first-page":"1090","DOI":"10.1038\/eye.2013.139","article-title":"Quality of bevacizumab compounded for intravitreal administration","volume":"27","author":"Palmer","year":"2013","journal-title":"Eye (Lond)"},{"issue":"10","key":"bib38","doi-asserted-by":"publisher","first-page":"1726","DOI":"10.1038\/s41433-020-0853-9","article-title":"Brolucizumab and Immunogenicity","volume":"34","author":"Sharma","year":"2020","journal-title":"Eye (Lond)"},{"key":"bib2","author":"Genentech"},{"key":"bib9","author":"EMEA"},{"key":"bib10","author":"Novartis"},{"key":"bib15","first-page":"1","volume-title":"<789>Particulate Matter in Ophthalmic Solutions","author":"United States Pharmacopeial Convention","year":"2018","edition":"41st ed."}],"container-title":["Translational Vision Science & Technology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/tvst.arvojournals.org\/article.aspx?articleid=2776613","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,18]],"date-time":"2021-08-18T15:45:15Z","timestamp":1629301515000},"score":1,"resource":{"primary":{"URL":"https:\/\/tvst.arvojournals.org\/article.aspx?articleid=2776613"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,18]]},"references-count":38,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2021,8,2]]}},"URL":"https:\/\/doi.org\/10.1167\/tvst.10.9.21","relation":{},"ISSN":["2164-2591"],"issn-type":[{"value":"2164-2591","type":"print"}],"subject":[],"published":{"date-parts":[[2021,8,18]]}}}